Symbols / JUNS Stock $0.33 -1.78% Jupiter Neurosciences, Inc.

Healthcare • Biotechnology • United States • NCM
JUNS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Christer Rosen
Exch · Country NCM · United States
Market Cap 11.98M
Enterprise Value 13.51M
Income -8.64M
Sales 21.80K
FCF (ttm) -2.31M
Book/sh -0.05
Cash/sh 0.10
Employees 5
Insider 10d —
IPO Dec 03, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 5.50
PEG —
P/S 549.81
P/B -6.23
P/C —
EV/EBITDA —
EV/Sales 620.01
Quick Ratio 0.51
Current Ratio 0.65
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.25
EPS next Y 0.06
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-14
Earnings (prior) 2025-11-14
ROA -94.64%
ROE -7.39%
ROIC —
Gross Margin 0.00%
Oper. Margin -128.87%
Profit Margin 0.00%
Shs Outstand 36.28M
Shs Float 18.33M
Insider Own 54.26%
Instit Own 4.95%
Short Float 0.32%
Short Ratio 0.75
Short Interest 68.14K
52W High 3.33
vs 52W High -90.08%
52W Low 0.31
vs 52W Low 7.94%
Beta —
Impl. Vol. —
Rel Volume 0.31
Avg Volume 123.47K
Volume 38.79K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.34
Price $0.33
Change -1.78%
About

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.33
Latest analyst target
3. DCF / Fair value
$-1.15
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.33
Low
—
High
—
Mean
—
News
RSS: Latest JUNS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-07-01 ROSEN CHRISTER Chief Executive Officer — 3,600 $1.01 $3,667
2025-07-01 SILVA ALISON D President — 750 $1.03 $772
2025-06-30 ROSEN CHRISTER Chief Executive Officer — 7,816 $0.98 $7,986
2025-06-30 SILVA ALISON D President — 1,800 $1.00 $1,855
2025-06-02 ELMASRI SALEEM C Chief Financial Officer — 66,293 — —
2025-06-02 ROSEN CHRISTER Chief Executive Officer — 973,466 — —
2025-06-02 SILVA ALISON D President — 110,227 — —
2025-01-22 WEIS HOLGER Director — 10,781 $2.80 $30,187
2025-01-22 BRADY ALLISON W Director — 21,750 $2.80 $60,900
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.02
0.00
0.00
-100.00%
0.23
Operating Revenue
0.02
0.00
0.00
-100.00%
0.23
Cost Of Revenue
0.00
—
—
—
Reconciled Cost Of Revenue
0.00
—
—
—
Gross Profit
0.02
—
—
—
Operating Expense
8.93
+188.76%
3.09
-20.14%
3.87
+5.59%
3.67
Research And Development
2.09
+323.53%
0.49
-48.40%
0.95
+1.27%
0.94
Selling General And Administration
6.84
+163.21%
2.60
-10.88%
2.92
+7.09%
2.72
General And Administrative Expense
6.84
+163.21%
2.60
-10.88%
2.92
+7.09%
2.72
Other Gand A
6.84
+163.21%
2.60
-10.88%
2.92
+7.09%
2.72
Total Expenses
8.93
+188.89%
3.09
-20.14%
3.87
+5.59%
3.67
Operating Income
-8.91
-188.19%
-3.09
+20.14%
-3.87
-12.77%
-3.43
Total Operating Income As Reported
-8.91
-188.19%
-3.09
+20.14%
-3.87
-12.77%
-3.43
EBITDA
-8.58
-291.50%
-2.19
+52.00%
-4.56
-8.26%
-4.22
Normalized EBITDA
-8.58
-186.37%
-3.00
+21.70%
-3.83
-11.48%
-3.43
EBIT
-8.58
-291.50%
-2.19
+52.00%
-4.56
-8.26%
-4.22
Total Unusual Items
0.00
-100.00%
0.80
+208.83%
-0.74
+5.82%
-0.78
Total Unusual Items Excluding Goodwill
0.00
-100.00%
0.80
+208.83%
-0.74
+5.82%
-0.78
Special Income Charges
0.00
-100.00%
0.86
+196.60%
-0.89
+15.22%
-1.05
Other Special Charges
—
-0.86
-196.60%
0.89
-15.22%
1.05
Net Income
-8.64
-254.35%
-2.44
+49.00%
-4.78
+3.51%
-4.96
Pretax Income
-8.64
-254.35%
-2.44
+49.00%
-4.78
+3.51%
-4.96
Net Non Operating Interest Income Expense
-0.07
+72.81%
-0.24
-11.27%
-0.22
+70.52%
-0.74
Interest Expense Non Operating
0.07
-73.42%
0.25
+13.56%
0.22
-70.48%
0.74
Net Interest Income
-0.07
+72.81%
-0.24
-11.27%
-0.22
+70.52%
-0.74
Interest Expense
0.07
-73.42%
0.25
+13.56%
0.22
-70.48%
0.74
Interest Income Non Operating
0.00
-100.00%
0.01
+1052.90%
0.00
-21.88%
0.00
Interest Income
0.00
-100.00%
0.01
+1052.90%
0.00
-21.88%
0.00
Other Income Expense
0.33
-63.12%
0.89
+228.76%
-0.69
+11.49%
-0.78
Other Non Operating Income Expenses
0.33
+266.49%
0.09
+102.25%
0.04
—
Gain On Sale Of Security
—
-0.05
-135.80%
0.15
-43.34%
0.26
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-8.64
-254.35%
-2.44
+49.00%
-4.78
+3.51%
-4.96
Net Income From Continuing Operation Net Minority Interest
-8.64
-254.35%
-2.44
+49.00%
-4.78
+3.51%
-4.96
Net Income From Continuing And Discontinued Operation
-8.64
-254.35%
-2.44
+49.00%
-4.78
+3.51%
-4.96
Net Income Continuous Operations
-8.64
-254.35%
-2.44
+49.00%
-4.78
+3.51%
-4.96
Normalized Income
-8.64
-166.48%
-3.24
+19.79%
-4.04
+3.07%
-4.17
Net Income Common Stockholders
-8.64
-254.35%
-2.44
+49.00%
-4.78
+3.51%
-4.96
Diluted EPS
—
-0.08
+55.56%
-0.18
-19.37%
-0.15
Basic EPS
—
-0.08
+55.56%
-0.18
-19.37%
-0.15
Basic Average Shares
—
28.78
+9.01%
26.41
-19.68%
32.88
Diluted Average Shares
—
28.78
+9.01%
26.41
-19.68%
32.88
Diluted NI Availto Com Stockholders
-8.64
-254.35%
-2.44
+49.00%
-4.78
+3.51%
-4.96
Line Item Trend 2025-12-31 2024-12-31 2021-12-31
Total Assets
5.56
-10.29%
6.20
—
Current Assets
4.82
+3.76%
4.65
—
Cash Cash Equivalents And Short Term Investments
3.79
+0.53%
3.77
—
Cash And Cash Equivalents
3.79
+0.53%
3.77
—
Cash Financial
3.79
+0.53%
3.77
—
Receivables
0.00
0.00
0.00
Accounts Receivable
0.00
0.00
—
Inventory
0.16
0.00
—
Prepaid Assets
0.77
+0.00%
0.77
—
Other Current Assets
0.11
-6.61%
0.11
—
Total Non Current Assets
0.74
-52.39%
1.55
—
Net PPE
0.02
-66.67%
0.07
—
Gross PPE
0.24
+0.00%
0.24
—
Accumulated Depreciation
-0.21
-27.91%
-0.17
—
Properties
0.00
0.00
—
Buildings And Improvements
0.24
+0.00%
0.24
—
Other Properties
—
—
0.21
Non Current Prepaid Assets
0.71
-51.85%
1.48
—
Other Non Current Assets
0.00
+0.00%
0.00
—
Total Liabilities Net Minority Interest
7.40
+264.26%
2.03
—
Current Liabilities
7.40
+268.11%
2.01
—
Payables And Accrued Expenses
0.68
+70.67%
0.40
—
Payables
0.13
-52.95%
0.28
—
Accounts Payable
0.13
-52.95%
0.28
—
Current Accrued Expenses
0.55
+360.45%
0.12
—
Pensionand Other Post Retirement Benefit Plans Current
1.40
-1.25%
1.42
—
Current Debt And Capital Lease Obligation
5.32
+2606.84%
0.20
—
Current Debt
5.30
+3518.11%
0.15
—
Other Current Borrowings
5.30
—
0.35
Current Capital Lease Obligation
0.02
-57.58%
0.05
—
Current Deferred Liabilities
0.00
0.00
—
Current Deferred Revenue
0.00
0.00
—
Other Current Liabilities
—
—
0.35
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.02
—
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.02
—
Long Term Debt
—
—
—
Long Term Capital Lease Obligation
0.00
-100.00%
0.02
—
Other Non Current Liabilities
—
—
—
Stockholders Equity
-1.83
-143.91%
4.17
—
Common Stock Equity
-1.83
-143.91%
4.17
—
Capital Stock
0.00
+4.05%
0.00
—
Common Stock
0.00
+4.05%
0.00
—
Preferred Stock
0.00
0.00
—
Share Issued
34.45
+4.06%
33.10
+0.01%
33.10
Ordinary Shares Number
34.45
+4.06%
33.10
+0.01%
33.10
Additional Paid In Capital
32.83
+8.75%
30.19
—
Retained Earnings
-34.67
-33.22%
-26.02
—
Total Equity Gross Minority Interest
-1.83
-143.91%
4.17
—
Total Capitalization
-1.83
-143.91%
4.17
—
Working Capital
-2.57
-197.34%
2.64
—
Invested Capital
3.47
-19.73%
4.32
—
Total Debt
5.32
+2342.73%
0.22
—
Net Debt
1.51
—
0.11
Capital Lease Obligations
0.02
-70.21%
0.07
—
Net Tangible Assets
-1.83
-143.91%
4.17
—
Tangible Book Value
-1.83
-143.91%
4.17
—
Current Notes Payable
0.00
-100.00%
0.15
—
Interest Payable
0.04
+3643.33%
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.41
-38.42%
-3.91
-713.18%
-0.48
+61.48%
-1.25
Cash Flow From Continuing Operating Activities
-5.41
-38.42%
-3.91
-713.18%
-0.48
+61.48%
-1.25
Net Income From Continuing Operations
-8.64
-254.35%
-2.44
+49.00%
-4.78
+3.51%
-4.96
Other Non Cash Items
0.71
+1121.51%
0.06
+246.46%
0.02
-97.01%
0.56
Stock Based Compensation
2.42
+31.38%
1.84
+53.59%
1.20
+46.66%
0.82
Operating Gains Losses
—
-0.80
-208.83%
0.74
-5.82%
0.78
Gain Loss On Investment Securities
—
0.05
+135.80%
-0.15
+43.34%
-0.26
Change In Working Capital
0.11
+104.11%
-2.57
-209.26%
2.35
+51.61%
1.55
Change In Receivables
-0.00
0.00
—
—
Changes In Account Receivables
-0.00
0.00
—
—
Change In Inventory
-0.16
0.00
—
—
Change In Prepaid Assets
0.00
+100.00%
-2.41
-48658.16%
0.00
—
Change In Payables And Accrued Expense
0.26
+275.33%
-0.15
-106.41%
2.34
+57.18%
1.49
Change In Accrued Expense
0.02
+3725.69%
-0.00
-100.03%
2.18
+40.81%
1.55
Change In Payable
0.24
+261.95%
-0.15
-190.69%
0.16
+392.97%
-0.06
Change In Account Payable
0.24
+261.95%
-0.15
-190.69%
0.16
+392.97%
-0.06
Change In Other Working Capital
0.00
—
—
—
Change In Other Current Assets
0.00
+317.93%
-0.00
-7240.00%
0.00
-99.96%
0.06
Financing Cash Flow
5.43
-28.99%
7.65
+1619.56%
0.45
-54.70%
0.98
Cash Flow From Continuing Financing Activities
5.43
-28.99%
7.65
+1619.56%
0.45
-54.70%
0.98
Net Issuance Payments Of Debt
5.43
+344.41%
-2.22
-670.05%
0.39
-60.30%
0.98
Issuance Of Debt
5.58
+3928.88%
0.14
-64.49%
0.39
-60.30%
0.98
Repayment Of Debt
-0.15
+93.80%
-2.36
0.00
—
Long Term Debt Issuance
5.58
+3928.88%
0.14
-64.49%
0.39
-60.30%
0.98
Long Term Debt Payments
-0.15
+93.80%
-2.36
0.00
—
Net Long Term Debt Issuance
5.43
+344.41%
-2.22
-670.05%
0.39
-60.30%
0.98
Short Term Debt Issuance
—
—
0.39
0.00
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
0.39
0.00
Net Common Stock Issuance
0.00
-100.00%
9.88
+17854.93%
0.06
0.00
Proceeds From Stock Option Exercised
—
—
—
—
Net Other Financing Charges
—
—
—
—
Changes In Cash
0.02
-99.47%
3.74
+10505.34%
-0.04
+86.49%
-0.27
Beginning Cash Position
3.77
+13136.57%
0.03
-55.80%
0.06
-80.51%
0.33
End Cash Position
3.79
+0.53%
3.77
+13136.57%
0.03
-55.80%
0.06
Free Cash Flow
-5.41
-38.42%
-3.91
-713.18%
-0.48
+61.48%
-1.25
Interest Paid Supplemental Data
0.04
-74.00%
0.15
+425.37%
0.03
-65.49%
0.08
Income Tax Paid Supplemental Data
—
0.00
0.00
0.00
Change In Interest Payable
0.04
-16.40%
0.05
+21.16%
0.04
-11.26%
0.04
Common Stock Issuance
0.00
-100.00%
9.88
+17854.93%
0.06
0.00
Issuance Of Capital Stock
0.00
-100.00%
9.88
+17854.93%
0.06
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category